Date posted: February 20, 2018, 6:00 am
In this episode, we will discuss some important factors to consider in management of various anticoagulants. We will also provide agent specific pharmacodynamic and pharmacokinetic based recommendations.
Date posted: January 30, 2018, 6:00 am
In this episode, we discuss the efficacy and safety of probiotics for the prevention of antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea (CDAD).
Date posted: January 9, 2018, 6:00 am
In this episode, we will review the surprising results of the VA/DoD’s 2017 Clinical Practice Guidelines on Management of PTSD, particularly as it relates to the use of one particular agent, prazosin.
Date posted: December 19, 2017, 6:00 am
In this episode, we review the important changes in 2017 ACC/AHA guidelines for hypertension management in adults
Date posted: November 28, 2017, 6:00 am
In this episode, we discuss the difficulty in identifying adverse drug reactions (ADR) that ACTUALLY occur from a drug therapy, how tertiary drug references (such as Micromedex or LexiComp) may be misleading, and what tips and tricks you can use to recognize the most clinically relevant ADRs for patient counseling.
Date posted: November 7, 2017, 6:00 am
In this episode, we interview Dylan Moe, PharmD, our very own alumnus, regarding the new Illinois rule requiring patient counseling for all new prescriptions and inquire how the new rule has impacted his pharmacy, work environment, and his opinions on the implementation of the rule.
Date posted: October 17, 2017, 6:00 am
In this episode, we will discuss the current state of benzodiazepine use, expected trends in prescribing, and risks associated with use. Lastly, we will discuss techniques for ensuring that a benzodiazepine taper is performed in a safe manner with lowest risk of harm.
Date posted: September 26, 2017, 6:00 am
In this episode, we discuss new evidence for cardiovascular outcomes in diabetics based on the LEADER trial (liraglutide) and CANVAS trials (canagliflozin). We also discuss the new FDA warning for canagliflozin regarding amputation risk.
Date posted: September 5, 2017, 6:00 am
In this episode, we discuss updates in diabetes management that includes nuances from the ADA’s Standards of Care 2017. We also review some newer pharmacologic agents, a fixed dose GLP-1 agonist and basal insulin combinations.
Date posted: August 15, 2017, 6:00 am
In this episode, we discuss three "older" antihypertensives that are not preferred first-line therapies: clonidine, methyldopa, and minoxidil. We outline why these agents are not first-line therapies and review their pharmacology and adverse effect profiles.